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carbohydrates and exposed only after CD4 bindingCCR5 Mimicry by Sulfated Human
occurs. Prototypic broadly neutralizing monoclonal anti-Anti-HIV-1 Antibodies bodies (mAbs) 17b and 48d that bind to this CD4-
induced epitope have been described (Wyatt and So-
droski, 1998), although their activity is weak, and their
ability to access this site is likely limited.
HIV-1 envelope glycoprotein interaction with a princi- In this issue of Cell, Choe et al. (2003) evaluate several
pal coreceptor, CCR5, requires sulfated tyrosines on new neutralizing human mAbs and make the remarkable
the CCR5 amino terminus. In this issue of Cell, Choe et observation that they are modified through sulfation of
al. identified tyrosine-sulfated, neutralizing antibodies tyrosines in their heavy chain CDR3 domains. This sec-
against HIV-1 that apparently mimic CCR5. The results ondary modification was critical to their ability to bind
demonstrate for the first time that a natural posttrans- gp120 and to neutralize virus, and could be inhibited by
lational modification of an antibody can contribute sulfated peptides based on the CCR5 amino terminus.
substantially to antigen recognition. Thus, similar to the interaction of the CCR5 amino termi-
nus with gp120 and -chemokines, the activity of these
antibodies was dependent on tyrosine sulfation, show-One of the greatest challenges in developing a vaccine
ing how a humoral immune response can mimic bothto HIV is the need to produce immunogens that can
pathologic and physiologic ligands. Moreover, severalelicit potent, long-lasting, and broadly neutralizing anti-
mAbs were formed from D and J regions that yield anbodies. Following infection, HIV continues to replicate
extended CDR3 domain, which probably facilitates notactively in the face of host cellular and humoral immune
only tyrosine sulfation but also antibody access to thisresponses. While type-specific neutralizing antibodies
conserved region.are made early, viral escape mutants are rapidly gener-
In the context of HIV pathogenesis, these novel find-ated, and broadly neutralizing antibodies are either not
ings raise several important issues and questions. Givenproduced or are produced late and in low titers (Wyatt
that the mAbs studied by Choe et al. (2003) were derivedand Sodroski, 1998). The basis for HIV’s ability to evade
from infected individuals, it is clear that tyrosine sulfationthe humoral immune response likely arises from a num-
is part of the natural humoral immune response to HIV.ber of structural attributes of its envelope glycoproteins,
However, it is not known how frequently such antibodiesincluding exposed hypervariable loops that can tolerate
are produced, when during the course of infection theymutations, extensive glycosylation, steric barriers that
appear, or whether their presence correlates with neu-restrict antibody access, and an intrinsic flexibility of
tralizing activity or clinical outcome. With a single excep-gp120 that may preclude formation and recognition of
tion (mAb E51), the sulfated antibodies evaluated neu-key epitopes (Kwong et al., 2002; Wei et al., 2003). These
tralized R5- but not X4-tropic viruses, consistent with
problems are likely compounded by the native trimeric
findings that X4 isolates were less dependent on sul-
structure of envelope oligomers on virions, the ability
fated tyrosines in the CXCR4 amino terminus (Farzan et
of conserved domains to remain concealed until after al., 2002). Could the presence of such antibodies in vivo
CD4 binding, and further steric barriers established on play a role in driving a switch in coreceptor usage from
the target cell as CD4 and chemokine receptors are CCR5 to CXCR4? Interestingly, E51, although sulfated,
engaged. bound to and neutralized X4 as well as R5 isolates,
HIV entry is initiated by the binding of gp120 to CD4 similar to nonsulfated mAbs 17b and 48d, which also
and a subsequent interaction with chemokine receptors have epitopes overlapping the bridging sheet domain.
CCR5 and/or CXCR4 (Wyatt and Sodroski, 1998). CD4 The role that tyrosine sulfation plays in the ability of
binds to a highly conserved but recessed pocket on the E51 to bind R5- as well as X4-tropic isolates will be of
gp120 core. Following binding, extensive conforma- interest. In addition, it will be interesting to elucidate the
tional changes occur in gp120, involving movement of basis for the observed variable sensitivity among R5
hypervariable loops V1/V2 and V3 and the formation of isolates to different sulfated antibodies and whether the
the “bridging sheet,” a four-stranded antiparallel  sheet neutralization activity of these antibodies results from
consisting of the V1/V2 stem and the 4th conserved do- binding to free virions or to cell-associated virus after
main of gp120. The V3 loop interacts with extracellular it has engaged CD4 and/or chemokine receptors. Fi-
loops on chemokine receptors and determines the spec- nally, if antibodies such as the ones described by Choe
ificity of chemokine receptor utilization, while conserved et al. (2003) can actually prevent HIV infection, identi-
residues within and adjacent to the bridging sheet bind fying immunogens that elicit them will be critical.
the chemokine receptor’s amino terminus (Dragic, 2001; Aside from the implications of these findings for HIV
Farzan et al., 2000). Interestingly, at least for CCR5 bind- pathogenesis, the report by Choe et al. (2003) represents
ing, this latter interaction is dependent upon sulfated the first example of a naturally occurring secondary
tyrosine residues within the CCR5 amino terminus (Far- modification of an antibody as a determinant of its speci-
zan et al., 1999), although this secondary modification ficity. Given that D regions frequently encode tyrosines
may be less important for CXCR4 utilization (Farzan et adjacent to aspartic acid residues, a known sulfation
al., 2002). The bridging sheet domain, while conserved, motif, it is likely that many other sulfated antibodies
will be identified. In the future, it will be important tois typically masked by the variable loops and flanking
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determine under what circumstances sulfation of tyro- The TNF Receptor 1:
sine residues occurs in other antibodies, how it is regu- A Split Personality Complexlated, and to what extent it contributes to humoral im-
mune responses in immunologic disorders and to other
pathogens. In light of these results, there may also be
other naturally occurring posttranslational modifications The tumor necrosis factor receptor 1 (TNFR1), a proto-
that impact antibody specificity and/or affinity. typic member of the death receptor family signals both
Structural and mechanistic insights into HIV envelope cell survival and apoptosis. In this issue of Cell, Mi-
glycoprotein function have led to a deeper understand- cheau and Tschopp (2003) report that apoptotic TNFR1
ing of the obstacles to producing broadly neutralizing signaling proceeds via the sequential formation of two
antibodies. However, the findings of Choe et al. (2003) distinct complexes. Since the first complex can acti-
as well as new insights into the structural basis for HIV vate survival signals and influence the activity of the
neutralization by other mAbs (Calarese et al., 2003; second complex, this mechanism provides a check-
Saphire et al., 2001; Sharon et al., 2003) provide hope point to control the execution of apoptosis.
that some humoral responses can contain and/or pre-
vent HIV infection. Modified envelope proteins that ex- TNFR1 has pleiotropic activities such as induction of
pose cryptic epitopes, redirect immune responses to apoptosis and activation of the transcription factor
conserved sites, preserve the native oligomeric struc- NF-B, leading to the induction of a number of antiapo-
ture, and/or decrease entropic barriers are all possible ptotic proteins. Despite the extensive study of this re-
approaches and will need to be linked to a growing ceptor, the mechanism governing the decision to induce
understanding of the full conformational repertoire avail- one of these pathways over the other is very poorly
able to antibodies that can overcome steric and other understood. After the identification of the components
barriers. The challenges in this field remain great, but of the death inducing signaling complex (DISC) of the
the problems are at least better defined, and step- related death receptor CD95 (APO-1/Fas) (Peter and
pingstones for further investigation are clearly in place. Krammer, 2003), it was widely assumed that TNFR1
would also recruit the adaptor FADD and caspase-8
upon binding of the ligand TNF to initiate apoptosis.George Lin1 and James A. Hoxie
This model was supported by data from cells of FADDDepartment of Medicine
or caspase-8-deficient mice in which TNF-induced apo-Hematology-Oncology Division
ptosis was impaired (Varfolomeev et al., 1998, Yeh etUniversity of Pennsylvania
al., 1998). However, attempts to demonstrate a directPhiladelphia, Pennsylvania 19104
physical association of FADD and caspase-8 with
1Present address: Biological Mimetics, Inc., 124 Byte Drive, Freder- TNFR1 failed (Harper et al., 2003), while the antiapo-
ick, MD 21702
ptotic components of the signaling complex, TRAF-2,
TRADD, and c-IAP1 were readily detected (Shu et al.,Selected Reading
1996).
Calarese, D.A., Scanlan, C.N., Zwick, M.B., Deechongkit, S., Mimura, In this issue of Cell, Micheau and Tschopp (2003)
Y., Kunert, R., Zhu, P., Wormald, M.R., Stanfield, R.L., Roux, K.H., confirmed that FADD and caspase-8 are not recruited
et al. (2003). Science 300, 2065–2071. to the activated receptor and provided an explanation
Choe, H., Li, W., Wright, P.L., Vasilieva, N., Venturi, M., Huang, C.-C., for the long standing mystery of how caspase-8 is acti-
Grundner, C., Zwick, M.B., Wang, L., Rosenberg, E.S., et al. (2003).
vated in cells that die through TNFR1 (Figure 1). LateCell 114, 161–170, this issue.
after stimulation, FADD and caspase-8 were found in a
Dragic, T. (2001). J. Gen. Virol. 82, 1807–1814.
complex with a number of other proteins that were ini-
Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M.,
tially recruited to TNFR1. However, this complex noGerard, N.P., Gerard, C., Sodroski, J., and Choe, H. (1999). Cell 96,
longer contained the receptor. These findings suggest667–676.
that following stimulation the complex that is originallyFarzan, M., Vasilieva, N., Schnitzler, C.E., Chung, S., Robinson, J.,
formed (complex I) dissociates from TNFR1 and formsGerard, N.P., Gerard, C., Choe, H., and Sodroski, J. (2000). J. Biol.
Chem. 275, 33516–33521. a different complex in the cytosol (complex II), which
Farzan, M., Babcock, G.J., Vasilieva, N., Wright, P.L., Kiprilov, E., then recruits the apoptotic machinery. The authors sug-
Mirzabekov, T., and Choe, H. (2002). J. Biol. Chem. 277, 40397– gest that this could be mediated by a change in the
40402. accessibility of the death domain (DD), a sequence re-
Kwong, P.D., Doyle, M.L., Casper, D.J., Cicala, C., Leavitt, S.A., quired for protein-protein interactions, in some of the
Majeed, S., Steenbeke, T.D., Venturi, M., Chaiken, I., Fung, M., et proteins initially recruited to the receptor such as the
al. (2002). Nature 420, 678–682.
adaptor protein TRADD. As the dissociation occurs
Saphire, E.O., Parren, P.W., Pantophlet, R., Zwick, M.B., Morris,
TRADD’s DD is free to recruit other DD containing pro-G.M., Rudd, P.M., Dwek, R.A., Stanfield, R.L., Burton, D.R., and
teins such as FADD and assembles complex II. But whatWilson, I.A. (2001). Science 293, 1155–1159.
is the signal for complex I to leave the cell surface?Sharon, M., Kessler, N., Levy, R., Zolla-Pazner, S., Gorlach, M., and
When complex I is formed at the receptor, it resultsAnglister, J. (2003). Structure (Camb.) 11, 225–236.
in the posttranslational modification of several of itsWei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Sala-
components, including the receptor itself as well aszar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al.
(2003). Nature 422, 307–312. TRADD and the serine/threonine kinase RIP, which has
Wyatt, R., and Sodroski, J. (1998). Science 280, 1884–1888. been shown to be required for the TNFR1-mediated
activation of NF-B. The observed increase in molecular
